QUOTE AND NEWS
FierceBiotech  Jul 29  Comment 
Sanofi's combination of a Type 2 diabetes treatment and a long-acting insulin met its main goal in a Phase III trial, the company said, setting up an FDA application later this year.
GenEng News  Jul 27  Comment 
The shift from fully integrated pharmaceutical companies (FIPCOs) to virtually integrated pharma companies (VIPCOs) has made biopharmas more reliant on external R&D. Often, that external R&D comes from startups nurtured through the venture funds...
FierceBiotech  Jul 23  Comment 
KalVista Pharmaceuticals has persuaded Novo A/S, SV Life Sciences and some other notable VCs to part with $33 million (€29 million). The cash will go toward advancing KalVista's pipeline of plasma kallikrein inhibitors, the most advanced of...
Benzinga  Jul 15  Comment 
Below are the top NYSE stocks in the healthcare sector in terms of return on investment. The trailing-twelve-month return on investment at Novo Nordisk A/S (ADR) (NYSE: NVO) is 65.50 percent. Novo Nordisk's revenue for the same period is $14.00...
Motley Fool  Jul 11  Comment 
Enrollment is complete in Pfizer and Opko Health's phase 3 study of hGH-CTP for human growth hormone deficiency.
FierceBiotech  Jul 10  Comment 
Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug--a key part of the pipeline--slashed HbA1c levels by 1.5% and 1.6%.





You may also be interested in articles related to Novo Nordisk A/S (NVO):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki